Gapping up
In reaction to earnings/guidance:
- NGVC +16.6% (also declares special dividend of $2/sh), QFIN +9.3%, CAL +9%, WSM +7.3%, HIBB +5.9%, OOMA +4.4%, ROST +4.3%, FL +3.9%, BKE +3.1%, BNR +2.8%, HHR +2.2%
Other news:
- MESO +15.5% (MESO and NVS sign license and collaboration agreement for remestemcel-L)
- FEYE +15.1% (acquires Respond Software; also announces $400 mln investment led by Blackstone)
- AMRN +13.9% (shares Phase 3 Study of VASCEPA)
- LGVW +8.5% (Medical imaging company Butterfly Network to be listed on NYSE through a merger with Longview Acquisition Corp)
- BNTX +7.2% (Pfizer and BioNTech (BNTX) to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine)
- AFMD +3.7% (announces publication of results Phase 1b study of AFM13)
- ADAP +3.4% (to showcase market potential for SPEAR T-cell Portfolio and pipeline with multiple cell therapy platforms)
- AZN +2.1% (receives FDA approval for less-frequent, fixed-dose use of Imfinzi)
- PFE +2.1% (Pfizer and BioNTech (BNTX) to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine)
- GPRO +1.9% (prices offering of $125.0 mln of 1.25% convertible senior notes due 2025)
- MNKD +1.8% (receives $12.5 mln milestone payment from UTHR)
- TRVN +1.6% (announces publication highlighting GI tolerability profile of Olinvyk injection in pain and therapy)
- SNAP +0.9% (buys app similar to TikTok, according to Business Insider)
Analyst comments:
- ATRO +6.5% (upgraded to Buy from Hold at Canaccord Genuity)
- CPRI +5% (upgraded to Buy from Neutral at BTIG Research)
- CLF +3.5% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- HEES +2.8% (upgraded to Buy from Underperform at BofA Securities)
- SCHN +2.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- SPR +2.2% (upgraded to Buy from Hold at Canaccord Genuity)
- OXY +1.9% (upgraded to Positive from Neutral at Susquehanna)
- URI +1.9% (upgraded to Buy from Neutral at BofA Securities)
- CG +1.8% (upgraded to Buy from Underperform at BofA Securities)
- LEG +1.3% (upgraded to Buy from Neutral at Goldman)